• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT GMBH ARCHITECT CA19-9XR REAGENT KIT; SYSTEM, TEST, CARBOHYDRATE AG (CA19-9), FOR MONIT AND MGMT OF PANCREATIC CANCER

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT GMBH ARCHITECT CA19-9XR REAGENT KIT; SYSTEM, TEST, CARBOHYDRATE AG (CA19-9), FOR MONIT AND MGMT OF PANCREATIC CANCER Back to Search Results
Catalog Number 02K91-24
Device Problem Low Test Results (2458)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 09/21/2021
Event Type  malfunction  
Manufacturer Narrative
Patient identifier: multiple sids for one patient = (b)(6).An evaluation is in process.A follow-up report will be submitted when the evaluation is complete.
 
Event Description
The customer observed falsely depressed architect ca19-9xr results for one patient.The following data was provided: on (b)(6) 2021, sid (b)(6), initial ca 19-9xr result was 156.89 u/ml, repeated >1200 u/ml, automatically diluted to 1:10 with a result of 10366 u/ml.On (b)(6) 2021, (same sample with new sid) sid (b)(6), initial result >1200 u/ml.No impact to patient management was reported.
 
Manufacturer Narrative
A ticket search by lot indicates that the reagent lot performs as expected for this product.Return testing was not completed as returns were not available.Trending review did not identify any trends for the complaint issue.Device history record review did not identify any issues associated with lot 23013m800 and the complaint issue.Historical performance of reagent lot 23013m800 was evaluated using worldwide data for the architect ca 19-9xr assay.The patient¿s data was analyzed and compared to an established control limit.This evaluation indicated that the patient median result for lot 23013m800 is within the established control limits.Therefore, no unusual reagent lot performance was identified for 23013m800.Labeling was reviewed and found to adequately address the issue under review.Based on the investigation, no systemic issue or deficiency of the architect ca 19-9xr reagent lot 23013m800 was identified.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ARCHITECT CA19-9XR REAGENT KIT
Type of Device
SYSTEM, TEST, CARBOHYDRATE AG (CA19-9), FOR MONIT AND MGMT OF PANCREATIC CANCER
Manufacturer (Section D)
ABBOTT GMBH
max-planck-ring 2
wiesbaden 65205
GM  65205
Manufacturer (Section G)
ABBOTT GMBH
max-planck-ring 2
wiesbaden 65205
GM   65205
Manufacturer Contact
christian lee
100 abbott park road
dept. 09b9, lc cp01-3
abbott park, IL 60064-3537
2246682940
MDR Report Key12605536
MDR Text Key278009520
Report Number3002809144-2021-00595
Device Sequence Number1
Product Code NIG
Combination Product (y/n)N
Reporter Country CodeFR
PMA/PMN Number
K052000
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional
Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup
Report Date 12/20/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received10/11/2021
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date12/11/2021
Device Catalogue Number02K91-24
Device Lot Number23013M800
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received12/06/2021
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured02/17/2021
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Treatment
ARC I2SR REFURB-SEKAT, 03M74-97, (B)(4); ARC I2SR REFURB-SEKAT, 03M74-97, (B)(4)
-
-